First-of-its-kind study finds a treatment effective for rheumatoid arthritis patients with lung disease
What you should know about thyroid cancer in adolescents, young adults
22 September 2022Research team finds new way to identify ‘safe harbor’ for gene therapies
22 September 2022First-of-its-kind study finds a treatment effective for rheumatoid arthritis patients with lung disease
For the first time, researchers have shown that a class of anti-fibrotic drugs slows the progression of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA). Research conducted in part at National Jewish Health showed that pirfenidone was safe and effective in these patients. The study, published earlier this month in the journal The Lancet Respiratory Medicine, is the first prospective treatment trial of patients with RA-ILD.
